Evidence map›Paper›PMID 34611589›Full record

ArticleJOR spine2021

Evaluation of lumbar spinal fusion utilizing recombinant human platelet derived growth factor-B chain homodimer (rhPDGF-BB) combined with a bovine collagen/β-tricalcium phosphate (β-TCP) matrix in an ovine model.

Benjamin C Gadomski, Kevin M Labus, Christian M Puttlitz, Kirk C McGilvray, Daniel P Regan, Brad Nelson, Howard B Seim, Jeremiah T Easley

Open access · goldAbstract read
In one paragraph

Article in JOR spine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Benjamin C GadomskiOrthopaedic Bioengineering Research Laboratory, Department of Mechanical Engineering and School of Biomedical Engineering Colorado State University Fort Collins Colorado USA.ORCID https://orcid.org/0000-0003-1434-0551
Kevin M LabusOrthopaedic Bioengineering Research Laboratory, Department of Mechanical Engineering and School of Biomedical Engineering Colorado State University Fort Collins Colorado USA.
Christian M PuttlitzOrthopaedic Bioengineering Research Laboratory, Department of Mechanical Engineering and School of Biomedical Engineering Colorado State University Fort Collins Colorado USA.ORCID https://orcid.org/0000-0002-1255-8867
Kirk C McGilvrayOrthopaedic Bioengineering Research Laboratory, Department of Mechanical Engineering and School of Biomedical Engineering Colorado State University Fort Collins Colorado USA.
Daniel P ReganDepartment of Microbiology, Immunology, and Pathology Colorado State University Fort Collins Colorado USA.
Brad NelsonPreclinical Surgical Research Laboratory, Department of Clinical Sciences Colorado State University Fort Collins Colorado USA.
Howard B SeimPreclinical Surgical Research Laboratory, Department of Clinical Sciences Colorado State University Fort Collins Colorado USA.
Jeremiah T EasleyPreclinical Surgical Research Laboratory, Department of Clinical Sciences Colorado State University Fort Collins Colorado USA.
Colorado State University · US

Funding

Elucidating the role and regulation of periostin in therapy-induced chemoresistance in metastatic breast cancerK01OD022982 · OD · COLORADO STATE UNIVERSITY · PI REGAN, DANIEL PATRICK · 2016 to 2021
$720k
NCATS NIH HHS L30 TR002126NIH HHS K01 OD022982
6 · The paper itself

Abstract

background contextWhile the clinical effectiveness of recombinant human Platelet Derived Growth Factor-B chain homodimer combined with collagen and β-tricalcium phosphate (rhPDGF-BB + collagen/β-TCP) treatment for indications involving hindfoot and ankle is well-established, it is not approved for use in spinal interbody fusion, and the use of autograft remains the gold standard. PURPOSE: The purpose of this study was to compare the effects of rhPDGF-BB + collagen/β-TCP treatment on lumbar spine interbody fusion in an ovine model to those of autograft bone and collagen/β-TCP treatments using biomechanical, radiographic, and histological assessment techniques. STUDY

designThirty-two skeletally mature Columbian Rambouillet sheep were used to evaluate the safety and effectiveness of rhPDGF-BB + collagen/β-TCP matrix in a lumbar spinal fusion model. Interbody polyetheretherketone (PEEK) cages contained either autograft, rhPDGF-BB + collagen/β-TCP, collagen/β-TCP matrix, or left empty.

methodsAnimals were sacrificed 8- or 16-weeks post-surgery. Spinal fusion was evaluated via post-sacrifice biomechanical, micro-computed tomography (μCT), and histological analysis. Outcomes were statistically compared using a two-way analysis of variance (ANOVA) with an alpha value of 0.05 and a Tukey post-hoc test.

resultsThere were no statistically significant differences between groups within treatment timepoints for flexion-extension, lateral bending, or axial rotation range of motion, neutral zone, neutral zone stiffness, or elastic zone stiffness. μCT bone volume fraction was significantly greater between treatment groups independent of timepoint where Autograft and rhPDGF-BB + collagen/β-TCP treatments demonstrated significantly greater bone volume fraction as compared to collagen/β-TCP (

conclusionsThe results of this study indicate that the use of rhPDGF-BB combined with collagen/β-TCP promotes spinal fusion comparable to that of autograft bone. CLINICAL SIGNIFICANCE: The data indicate that rhPDGF-BB combined with collagen/β-TCP promotes spinal fusion comparably to autograft bone treatment and may offer a viable alternative in large animal spinal fusion. Future prospective clinical studies are necessary to fully understand the role of rhPDGF-BB combined with collagen/β-TCP in human spinal fusion healing.

Indexed as

autograftcollagenfusiongrowth factorovinerhPDGF‐BBspineβ‐TCP

Identifiers

PMID34611589
PMCPMC8479519
OpenAlexW3179816360

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.